Report Overview

China GBS Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 4.5% during the forecast period.

Guillain-Barr (Ghee-yan Bah-ray) Syndrome is an inflammatory disorder of the peripheral nerves outside the brain and spinal cord. In China the number of patient inclusions per country per year is 98. Chinasestimated GBS incidence ratewas 0.180.32 cases/1,000 live births. Chinahad the second highest absolute numberof GBScases among infants globally with 25,000. The highest rates have been reported in adults, especially those aged over 75 years. Males are affected 1.5 times more often than females in all age groups.



Market Drivers

China is a growing market for GBS disease due to an increase in population (60 years and older-18.7%), increase in healthcare expenditure, Increase in microbial infections (zika virus infection) in China.

The increasing Chinas incidence rate (0.180.32 cases/1,000 live births) of GBS disease and increasing levels of awareness-related disease progression, etiology, and available therapies are leading to a high growth of GBS drugs market.

However, there are some restraining factors for the growth of GBS therapeutics market in China such as high cost of treatment, limitations of medical insurance coverage and misdiagnosis of the disease.